A recent study has brought to light a previously unacknowledged aspect of Alzheimer's disease: the presence of aggregated, compromised energy-producing units within neuronal filaments. Termed "mitochondrial plaques," these formations appear to stem from a malfunction in the brain's cellular waste removal mechanisms. The findings, detailed in Nature Neuroscience, propose that addressing these newly found aggregations, in conjunction with current treatment strategies, could provide a more thorough approach to decelerating cognitive deterioration.
Alzheimer's disease is a degenerative brain condition characterized by memory impairment and a decline in cognitive functions. For many years, therapeutic interventions have predominantly focused on amyloid plaques, which are anomalous protein clusters that accumulate outside brain cells. However, these treatments have offered only limited improvements, prompting researchers to investigate other cellular alterations associated with the disease.
Mitochondria, the powerhouses of cells responsible for energy generation, have become a focal point of investigation. When mitochondria sustain damage, cells initiate a recycling process known as mitophagy to eliminate them. During mitophagy, compromised mitochondria are transported to lysosomes, which are acidic compartments functioning as the cell's waste disposal system.
Should lysosomes fail to operate correctly, cellular debris can accumulate. A study from 2026 indicated that these cellular waste-disposal compartments begin to falter early in Alzheimer's disease, even preceding the formation of classic amyloid plaques. This early dysfunction helps to explain why damaged mitochondria might aggregate instead of being properly broken down.
In this latest research, scientists aimed to precisely map the mechanisms and locations where mitochondrial recycling falters. Xiuli Dan, a research assistant professor at the University of Minnesota, explained that previous work suggested mitophagy impairment in Alzheimer's brains. At that time, evidence was largely indirect, focusing on protein changes and mitochondrial accumulation without direct measurement of mitophagy or affected brain regions.
The endeavor to visually track mitochondrial breakdown in specific brain areas involved several research institutions. Dan mentioned that the project originated in Dr. Bohr's laboratory at NIH and concluded in Dr. Robbins' laboratory at UMN after her relocation. To investigate these questions, scientists utilized genetically altered mice engineered to manifest Alzheimer's-like symptoms. These mice were also modified to produce a fluorescent marker in their mitochondria that glows green in neutral environments but turns red in acidic lysosomes. This color-coding allowed researchers to precisely monitor which mitochondria were undergoing active digestion and which were merely suspended within the cell.
Utilizing this animal model, an unexpected discovery was made: acidic mitochondria accumulated distinctly and notably in the brains of mice with Alzheimer's-like conditions. This surprising observation prompted further investigation into these accumulations, ultimately leading to the identification and characterization of what the researchers now call mitochondrial plaques. The research team examined brain sections from these mice at various developmental stages using advanced microscopes. They also studied another mouse model of Alzheimer's disease and analyzed postmortem brain tissue from human Alzheimer's patients to validate their findings. The scientists observed substantial, anomalous aggregations of mitochondria within the cortex and hippocampus, brain regions crucial for memory. They designated these extensive clusters as "mitochondrial plaques." These structures exhibited a multilayered composition and were significantly larger than the typical mitochondrial recycling sites observed in healthy cells.
These mitochondrial plaques were specifically located within swollen, compromised segments of nerve fibers. Approximately 60 percent of the material inside a typical mitochondrial plaque was acidic, indicating its engulfment by lysosomes. The remaining portion consisted of mitochondria residing in a neutral environment, awaiting degradation. Observing the mice over time revealed that mitochondrial plaques emerge as early as 15 weeks of age, coinciding roughly with the onset of amyloid plaque formation. Initially, the brain attempts to compensate by dispatching more lysosomes to break down the mitochondrial accumulation. However, the lysosomes in the Alzheimer's models lacked the necessary acidity and enzymes to process the waste, leading to the mitochondria's accumulation. Eventually, these mitochondrial clusters frequently enlarged and coalesced with amyloid plaques, forming what researchers termed mixed plaques. Around 60 percent of the localized amyloid precursor protein was found encapsulated within these mitochondrial clusters. Nevertheless, the study indicates that mitochondrial plaques can also exist entirely independently of amyloid plaques, particularly in the disease's initial phases.
To confirm that this phenomenon is not confined to mice, the team examined postmortem hippocampal tissue from human Alzheimer's patients and age-matched healthy controls. The human Alzheimer's brains displayed the same extensive, mitochondria-rich clusters intimately associated with lysosomes. This characteristic was completely absent in healthy brains. Dan emphasized that the primary conclusion is that mitochondrial plaques (MPs) represent a previously unknown pathological structure in Alzheimer's disease, largely composed of mitochondria that become trapped and are not properly degraded within neurons. As with all scientific investigations, certain limitations must be considered. The study heavily relied on mouse models and a simplified cell-culture system to trace the progression of mitochondrial buildup. While these models offer a controlled environment for observing brain changes over time, they do not fully replicate the intricate nature of human Alzheimer's disease.
Several aspects regarding the precise sequence of events warrant attention. Although the imaging and molecular analyses suggest that mitochondrial accumulation precedes a compromised lysosomal response, the study cannot definitively establish the entire causal chain. Other pathological characteristics, such as tau protein tangles or chronic inflammation, might also contribute to the disruption of the brain's waste disposal systems. Dan concluded by stating that their findings propose that MP formation is not merely a problem of lysosomal degradation. The process appears to commence with an anomalous accumulation of mitochondria, followed by impaired lysosomal processing and clearance. She expressed hope that this discovery will offer a fresh perspective on mitochondrial pathology in Alzheimer's disease and potentially lead to the identification of new biomarkers or therapeutic targets. Future research will need to ascertain whether treatments aimed at enhancing lysosomal acidity and improving mitochondrial recycling can prevent the formation of these plaques. Addressing both amyloid and mitochondrial plaques concurrently could provide a more efficacious strategy for maintaining brain function.